More recently, the dihydroorotate dehydrogenase (DHODH) inhibitor BAY2402234 showed blood–brain barrier penetration and promising efficacy in IDH mutant glioma, diffuse midline glioma, and MYC-amplified medulloblastoma. This evidence concerns the gene DHODH and diffuse midline glioma.